Does alogliptin increase major adverse cardiovascular events in patients with type 2 diabetes who had had a recent acute coronary syndrome?
Alogliptin does not increase the risk of major adverse cardiovascular events in patients with type 2 diabetes and recent acute coronary syndrome.
Among patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo. (Funded by Takeda Development Center Americas; EXAMINE ClinicalTrials.gov number, NCT00968708.).
White et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: